| S7724 |
Eprenetapopt (APR-246)
|
Eprenetapopt (APR-246, PRIMA-1MET) is a small organic molecule that has been shown to restore tumour-suppressor function primarily to mutant p53 and also to induce cell death in various cancer types. It induces apoptosis and autophagy.
|
-
Oncotarget, 2024, 15:614-633
-
J Cell Mol Med, 2024, 28(9):e18374
-
Cell Death Dis, 2023, 14(11):783
|
|
| S2781 |
RITA
|
RITA induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and this compound also inhibits MDM2-p53 interaction by targeting p53.
|
-
PLOS ONE, 2026, e0343551
-
Cell Death Discov, 2024, 10(1):381
-
J Cancer, 2023, 14(2):200-218
|
|
| S1172 |
Serdemetan (JNJ-26854165)
|
Serdemetan (JNJ-26854165) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
|
-
Elife, 2025, 14e75393
-
J Physiol, 2025, 603(19):5477-5508
-
Signal Transduct Target Ther, 2022, 7(1):97
|
|
| S8483 |
CBL0137 Hydrochloride
|
CBL0137 (CBLC137, Curaxin 137) HCl activates p53 and inhibits NF-κB with EC50s of 0.37 μM and 0.47 μM in the cell-based p53 and NF-kB reporter assays, respectively. It also inhibits histone chaperone FACT (facilitates chromatin transcription complex).
|
-
Oncogene, 2025, 893-908
-
Oncogene, 2025, 44(13):893-908
-
Cancer Biology & Therapy, 2025, 2511301
|
|
| S8000 |
Tenovin-1
|
Tenovin-1 protects against MDM2-mediated p53 degradation, which involves ubiquitination, and acts through inhibition of protein-deacetylating activities of SirT1 and SirT2. This compound is also an inhibitor of dihydroorotate dehydrogenase (DHODH).
|
-
American Journal of Physiology-Renal Physiology, 2024, F326-F337
-
J Pharm Biomed Anal, 2021, 201:114121
-
J Transl Med, 2019, 17(1):76
|
|
| S7723 |
PRIMA-1
|
PRIMA-1 (2,2-Bis(hydroxymethyl)-3-quinuclidinone) is a mutant p53 reactivator. It induces apoptosis and inhibits growth of human tumors with mutant p53.
|
-
J Control Release, 2024, 371:111-125
-
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
-
J Pers Med, 2022, 12(2)258
|
|
| S7149 |
NSC 319726 (ZMC1)
|
NSC 319726 (ZMC1) is a p53(R175) mutant reactivator, exhibits growth inhibition in cells expressing mutant p53, with IC50 of 8 nM for p53(R175) mutant, shows no inhibition for p53 wild-type cells.
|
-
Cell Rep Med, 2025, S2666-3791(25)00102-8
-
Microbiol Spectr, 2021, 9(3):e0139521
-
Cell, 2020, 182(3):685-712.e19
|
|
| S8149 |
NSC348884
|
NSC348884, as a nucleophosmin inhibitor, inhibit cell proliferation and induce apoptosis in various cancer cell lines with IC50 values ranging from 1.4-4 µM.
|
-
Mol Cell, 2025, S1097-2765(25)00409-5
-
Front Immunol, 2022, 13:956991
-
Nat Commun, 2020, 3;11(1):1669
|
|
| S4900 |
Tenovin-6
|
Tenovin-6 is a small molecule activator of p53 transcriptional activity and inhibits dihydroorotate dehydrogenase (DHODH). This compound is also an inhibitor of SirT1 and SirT2.
|
-
Cell Death Dis, 2023, 14(10):667
-
Front Immunol, 2021, 12:685523
-
Biomed Pharmacother, 2020, 125:109948
|
|
| S8106 |
NSC59984
|
NSC59984 is a p53 pathway activator via induction of mutant p53 protein degradation and p73 activation.
|
-
Cancers (Basel), 2023, 15(3)745
-
J Clin Med, 2023, 12(23)7491
-
Front Bioeng Biotechnol, 2020, 8:538663
|
|
| S8580 |
COTI-2
|
COTI-2 is an orally available third generation thiosemicarbazone and activator of mutant forms of the p53 protein, with potential antineoplastic activity.
|
-
Biometals, 2025, 10.1007/s10534-025-00736-z
-
J Cell Mol Med, 2024, 28(9):e18374
-
DASH, 2020, None
|
|
| S5811 |
Kevetrin hydrochloride
|
Kevetrin hydrochloride (Thioureidobutyronitrile) is a water-soluble, small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity.
|
-
International Journal of Molecular Sciences, 2022, 10042
-
Int J Mol Sci, 2022, 23(17)10042
|
|
| E1971 |
Rezatapopt
|
Rezatapopt(PC14586) is a first-in-class p53 reactivator. It selectively binds to the mutated p53 Y220C protein and restores its wild-type activity. It can also be used to inhibit solid tumor with p53 mutation.
|
|
|
| E7154 |
C16-Ceramide
|
C16-Ceramide (N-Palmitoylsphingosine)is a sphingolipid ligand and an activator of p53 tumor suppressor. It tightly binds within the p53 DNA-binding domain with a Kd of ~ 60 nM, in close vicinity to the Box V motif. It regulates the protein ubiquitination and proteasomal degradation and also induces apoptosis in cancer cells making it a research tool for targeting human cancers.
|
|
|
| S2427 |
Triglycidyl Isocyanurate (Teroxirone)
|
Triglycidyl Isocyanurate (Teroxirone, Tris(2,3-epoxypropyl) Isocyanurate, TGI, TGIC) is a triazene triepoxide with antineoplastic activity. It inhibits growth of human non-small cell lung cancer cells by activating p53. This compound alkylates and cross-links DNA, thereby inhibiting DNA replication. It is also used in various polyester powder coatings in the metal finishing industry.
|
|
|
| S8059 |
Nutlin-3a
|
Nutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.
|
-
Nucleic Acids Res, 2025, 53(13)gkaf627
-
Cell Rep Med, 2025, 6(8):102284
-
Bone Res, 2025, 13(1):62
|
|
| S2341 |
(-)-Parthenolide
|
(-)-Parthenolide, an inhibitor of the Nuclear Factor-κB Pathway, specifically depletes HDAC1 protein without affecting other class I/II HDACs; Also promotes the ubiquitination of MDM2 and activates p53 cellular functions.
|
-
J Adv Res, 2025, S2090-1232(25)00353-4
-
Biomed Pharmacother, 2025, 188:118183
-
Cell Death Discov, 2025, 11(1):286
|
|
| S7649 |
SAR405838
|
SAR405838 is an orally available MDM2 antagonist with Ki of 0.88 nM. This compound is a diastereomer of MI-773 (CAS: 1303607-07-9). Phase 1.
|
-
Nat Genet, 2025, 57(1):140-153
-
Pharmaceutics, 2023, 15(4)1274
-
bioRxiv, 2023, 10.1101/2023.03.10.531074
|
|
| S0507 |
CBL0137
|
CBL0137 (Curaxin-137) is an inhibitor of the histone chaperone FACT (facilitates chromatin transcription) that simultaneously suppresses NF-κB and activates p53 with EC50 of 0.47 μM and 0.37 μM, respectively.
|
-
Oncogene, 2024, 893-908
-
Cancer Med, 2024, 13(20):e70288
-
STAR Protoc, 2024, 5(4):103446
|
|
| S2678 |
NSC 207895
|
NSC 207895 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.
|
-
PLoS One, 2024, e0295629
-
PLoS One, 2024, 19(1):e0295629
-
Front Oncol, 2021, 11:582511
|
|
| E3037 |
Solanum lyratum Extract
|
Solanum lyratum Extract (300 μg/ml) increases Bax levels and decreases Bcl-2 levels, which cause the loss of mitochondrial membrane potential (Δæm) followed by cytochrome C release and caspase-9 and -3 activation, finally leading to apoptosis. This compound also promotes p53 and p27, but decreases the levels of cyclin B1 thus causing S-phase arrest.
|
|
|
| S2176 |
Tenovin-3
|
Tenovin-3 is an inhibitor of SIRT2. This compound is able to increase p53 levels in MCF-7 cells.
|
|
|